RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zynerba Pharmaceuticals Stock

Zynerba Pharmaceuticals Equity 2024

Zynerba Pharmaceuticals Equity

46.23 M USD

Ticker

ZYNE

ISIN

US98986X1090

WKN

A14XCV

In 2024, Zynerba Pharmaceuticals's equity was 46.23 M USD, a -34.81% increase from the 70.91 M USD equity in the previous year.

Zynerba Pharmaceuticals Aktienanalyse

What does Zynerba Pharmaceuticals do?

Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Zynerba Pharmaceuticals's Equity

Zynerba Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zynerba Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Zynerba Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Zynerba Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Zynerba Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Zynerba Pharmaceuticals stock

What is the equity of Zynerba Pharmaceuticals this year?

Zynerba Pharmaceuticals has equity of 46.23 M USD this year.

What was the equity of Zynerba Pharmaceuticals compared to the previous year?

The equity of Zynerba Pharmaceuticals has increased/decreased by -34.81% decreased compared to the previous year.

What impact does a high equity have on investors of Zynerba Pharmaceuticals?

A high equity is advantageous for investors of Zynerba Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Zynerba Pharmaceuticals?

A low equity can be a risk for investors of Zynerba Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Zynerba Pharmaceuticals affect the company?

An increase in equity of Zynerba Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Zynerba Pharmaceuticals affect the company?

A reduction in equity of Zynerba Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Zynerba Pharmaceuticals?

Some factors that can affect the equity of Zynerba Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Zynerba Pharmaceuticals so important for investors?

The equity of Zynerba Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Zynerba Pharmaceuticals take to change the equity?

To change equity, Zynerba Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Zynerba Pharmaceuticals pay?

Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Zynerba Pharmaceuticals?

The current dividend yield of Zynerba Pharmaceuticals is .

When does Zynerba Pharmaceuticals pay dividends?

Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Zynerba Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zynerba Pharmaceuticals located?

Zynerba Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynerba Pharmaceuticals from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Zynerba Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Zynerba Pharmaceuticals in the year 2023?

In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.

In which currency does Zynerba Pharmaceuticals pay out the dividend?

The dividends of Zynerba Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zynerba Pharmaceuticals

Our stock analysis for Zynerba Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynerba Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.